Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus rating of “Hold” by the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $26.40.
SVRA has been the topic of a number of research reports. Roth Capital dropped their target price on shares of Savara from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st. Canaccord Genuity lifted their price target on shares of Savara from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. BidaskClub downgraded shares of Savara from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 9th. Ladenburg Thalmann Financial Services initiated coverage on shares of Savara in a research note on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price target on the stock. Finally, Zacks Investment Research downgraded shares of Savara from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd.
Shares of Savara (SVRA) traded up $0.20 during mid-day trading on Friday, reaching $11.80. 28,169 shares of the company were exchanged, compared to its average volume of 166,834. Savara has a fifty-two week low of $4.60 and a fifty-two week high of $17.19. The company has a market capitalization of $360.21, a price-to-earnings ratio of -2.82 and a beta of -0.26. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15.
WARNING: “Brokerages Set Savara Inc (SVRA) Price Target at $26.40” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/01/23/mast-therapeutics-inc-svra-receives-26-40-consensus-target-price-from-brokerages.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.